The Parkinson’s Foundation is expanding its Global Care Network with a membership program — called Community Partners in Parkinson’s Care — to better equip senior living communities and home care agencies to care for people with Parkinson’s disease. The foundation’s Global Care Network is made up of…
News
Centogene is expanding enrollment in the Rockstock International Parkinson’s Disease (ROPAD) gene study — the world’s largest research effort to characterize the genetic profile of people with Parkinson’s disease. The global study now will recruit participants at 48 sites across 10 countries: the U.S., Argentina, Brazil, the…
Neurocrine Biosciences has acquired rights to Voyager Therapeutics’ experimental gene therapy program for Parkinson’s disease associated with mutations in the GBA1 gene and for other GBA1-mediated diseases. The collaboration agreement also includes three gene therapy programs for rare diseases of the central nervous system (CNS;…
Fatty liver disease may not be among the risk factors for Parkinson’s in either men or women, according to a study in the Netherlands involving older people with liver problems. The new study found no link to an increased risk of the neurodegenerative disorder in this elderly European population.
A liquid formulation of levodopa/carbidopa (LD/CD) delivered continuously under the skin via a pump, ND0612 is more effective than oral LD/CD, a mainstay treatment, at controlling symptoms without causing dyskinesia, according to results from the Phase 3 BouNDless trial. With this finding, the trial met its primary goal —…
Certain pro-inflammatory gut bacteria, genes, and pathways are significantly increased in people with Parkinson’s disease compared with healthy people, while anti-inflammatory ones are significantly reduced, a large study found. Also, machine learning models based on 11 of these bacteria and six of these genes accurately discriminated between people with…
Analyses done by machine learning of data collected in brain imaging, clinical exams, and laboratory tests can be used to predict the risk of freezing of gait developing among people in the early stages of Parkinson’s disease, a study reported. The study, “Baseline cerebral structural morphology predict…
One year of treatment with Duopa, a levodopa/carbidopa intestinal gel, led to fast and sustained reductions in motor fluctuations and improved symptom control throughout the day among people with advanced Parkinson’s disease. That’s according to new analyses of data from a earlier large-scale Phase 3 clinical trial that…
Better adherence to Mediterranean-style diets is associated with lower patient-reported symptom severity in people with Parkinson’s disease, according to a study of more than 1,000 patients. Between the two evaluated diets — the Mediterranean (MEDI) and the Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) — the MIND diet was…
Golexanolone, an investigational small molecule from Umecrine Cognition, reversed cognitive and motor symptoms in a rat model of Parkinson’s disease, in addition to easing signs of fatigue, anxiety, and depression. The experimental therapy is in clinical development for hepatic encephalopathy and primary biliary cholangitis, two conditions marked by…
Recent Posts
- Enrollment complete in trial of experimental Parkinson’s treatment
- Finding agency amid the threat of Parkinson’s disease psychosis
- Resistance training study enrolling Parkinson’s disease patients
- New AI tool flags early risk of cognitive decline in Parkinson’s
- Even as his Parkinson’s progressed, Uncle Brandon cared for me, too